Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca sales decline slows as it waits for medicine to work

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 12:48pm CET
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

AstraZeneca's (>> AstraZeneca) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

AstraZeneca's (>> AstraZeneca) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

Product sales were down 3 percent compared with an 11 percent fall during the first half of the year. Emerging markets proved a bright spot, with Chinese sales up 12 percent, the company said on Thursday.

Chief Executive Pascal Soriot believes the drugmaker has reached a turning-point as its pipeline of new medicines starts to deliver and the impact of patent losses recedes. Consensus forecasts also point to a recovery in sales and profits from next year.

Still, the speed of AstraZeneca's turnaround remains uncertain as the No.2 British drugmaker goes head to head with industry giants like Roche (>> Roche Holding Ltd.), Bristol-Myers Squibb (>> Bristol-Myers Squibb Company) and Merck & Co (>> Merck and Company) in the fast-growing but fiercely competitive cancer drug market.

Total revenue rose 9 percent to $6.23 billion (£4.7 billion) in the quarter, helped by a $997 million payment from Merck, which struck a cancer drug partnership deal with the British group in July. Sales of Crestor, while down 16 percent, were also higher than expected.

That was not enough to stop a fall in core earnings per share (EPS), which exclude some items, of 15 percent to $1.12. But the overall results were better than expected and the shares had risen around 1 percent by 1130 GMT.

Industry analysts, on average, had forecast quarterly earnings of $1.04 and revenue of $5.95 billion, according to Thomson Reuters data.

For the full year, AstraZeneca said it expected 2017 core EPS to be "towards the favourable end of the guidance range of a low to mid teens percentage decline".

Soriot said he remained confident AstraZeneca could achieve annual revenue of more than $40 billion in 2023, despite scepticism among analysts like Trinity Delta's Mick Cooper who said it was "difficult" to see how this would be done.

Soriot first gave a bullish long-term forecast of 2023 revenue hitting $45 billion back in 2014, as he fended off a takeover attempt by Pfizer (>> Pfizer). Since then, a stronger dollar has shifted the target slightly but Soriot said the expectation in constant exchange rates had not changed.

"Our long-range plan so far reconfirms that we can get to the $40-41 billion dollars at today's currency rates that we communicated back in 2014," he said.


Results from drug trials remain critical.

AstraZeneca suffered the biggest ever daily fall in its shares three months ago, following the initial failure of a key lung cancer trial dubbed Mystic.

But it has since rebuilt investor expectations, helped by impressive data from two other lung cancer trials, involving the drugs Tagrisso and Imfinzi, that were presented at a medical congress in Madrid in September.

And just last week it won early U.S. approval for Calquence, marking its first entry into the blood cancer market.

However, results from another immunotherapy lung cancer trial called Arctic have been delayed again and are now not expected until the first half of 2018.

AstraZeneca is also refilling its drug pipeline in other areas, such as respiratory medicine. A new drug for severe asthma is awaiting U.S. approval by the end of this year and could get an approval recommendation in Europe as early as Friday.

(Reporting by Ben Hirschler; Editing by Keith Weir and Mark Potter)

By Ben Hirschler

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
11/21 ASTRAZENECA : Reports from AstraZeneca Describe Recent Advances in Liver Metasta..
11/21 ASTRAZENECA : New Findings from AstraZeneca in the Area of Alopecia Reported (Me..
11/21 ASTRAZENECA : Reports from Astrazeneca Describe Recent Advances in Medicinal Che..
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/21 ASTRAZENECA : FDA Approves Fasenra for Severe Asthma Stemming from Immune Cell G..
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimizes likely staff losses
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimises likely staff losses
11/20 FTSE recoups early losses as cyclicals recover
11/20 Innate Pharma SA - Third quarter 2017 report
11/20 ASTRAZENECA : New England Journal of Medicine Publishes Results of Phase III FLA..
More news
News from SeekingAlpha
11/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
11/20 Roche Rocks On With More Good News
11/20 Merck & Co. - Blue Chip Pharmaceutical At 52-Week Lows
11/20 YOUR DAILY PHARMA SCOOP : Geron's Fate, Celldex Commences Mid-Stage Study, Novar..
11/17 Denali Therapeutics Files To Raise $100 Million IPO
Financials ($)
Sales 2017 21 809 M
EBIT 2017 5 887 M
Net income 2017 2 298 M
Debt 2017 12 458 M
Yield 2017 4,10%
P/E ratio 2017 33,54
P/E ratio 2018 28,13
EV / Sales 2017 4,44x
EV / Sales 2018 4,43x
Capitalization 84 364 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 68,1 $
Spread / Average Target 2,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA12.11%84 364
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014